The bioengineered combo dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent in patients with chronic total occlusion evaluated by clinical outcome …
R Blessing, M Ahoopai, M Geyer, M Brandt… - Journal of clinical …, 2020 - mdpi.com
We sought to determine the effects of the use of a Bioengineered Combo Dual-Therapy
CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent (Combo® DTS) in patients with …
CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent (Combo® DTS) in patients with …
Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trials
EH Ploumen, E Semedo, CJM Doggen… - Netherlands Heart …, 2024 - Springer
Background Several ethnic minorities have an increased risk of cardiovascular events, but
previous European trials that investigated clinical outcome after coronary stenting did not …
previous European trials that investigated clinical outcome after coronary stenting did not …
[PDF][PDF] Comparison of Percutaneous Coronary Intervention and Optimal Medical Therapy on Outcomes in Patients with Chronic Coronary Total Occlusion
F Zhou, L Sun, Q Liu, N Wu, D Jia - 2021 - scholar.archive.org
Background: Nowadays the optimal strategy for patients with chronic total occlusion (CTO)
has not been well established. This meta-analysis aims to evaluate effect of PCI and optimal …
has not been well established. This meta-analysis aims to evaluate effect of PCI and optimal …